Page 21 - Alkermes News Today

The substance use disorder treatment market is expected to grow at a compound annual growth rate (CAGR) of 5.4% over the course of the forecast period, from US$ 7 Million in 2022 to US$ 14 Million by 2032.Substance Use Disorder Treatment Market: OverviewThe global market for substance use disorder treatment is expec...

/PRNewswire/ -- The "DNA Encoded Library: Platforms and Services Market (2nd Edition), 2023-2035" report has been added to ResearchAndMarkets.coms offering....

DUBLIN, Oct. 18, 2023 /PRNewswire/ -- Alkermes plc will host a conference call and webcast presentation at 8:00 a.m. ET on Wednesday, Oct. 25, 2023 to discuss the companys third quarter financial...

Virtu Financial LLC bought a new stake in Alkermes plc (NASDAQ:ALKS – Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 24,011 shares of the company’s stock, valued at approximately $752,000. Other large investors also recently made changes to their positions in the company. TCI […]

This study is the first to assess the efficacy of this drug combination in a real-world setting.

Alkermes will present new data on ALKS 2680, an investigational orexin-2 receptor agonist for narcolepsy, at World Sleep Congress. 

/PRNewswire/ -- Mural Oncology plc, the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans to establish in the fourth quarter of 2023...

StockNews.com began coverage on shares of Alkermes (NASDAQ:ALKS – Free Report) in a research note issued to investors on Thursday. The firm issued a strong-buy rating on the stock. ALKS has been the subject of several other reports. Cantor Fitzgerald reiterated an overweight rating on shares of Alkermes in a research report on Monday, July […]

One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...